Mental Health Innovations Discussed by NRx Pharmaceuticals and HOPE Therapeutics at Oppenheimer Conference

In an exciting development for the field of mental healthcare, NRx Pharmaceuticals and its subsidiary, HOPE Therapeutics, are set to headline the 8th Annual Neuroscience Innovation Forum in San Francisco. The keynote promises to explore the integration of Transcranial Magnetic Stimulation, Digital Therapeutics, and NMDA-targeted drug therapy.

Dr. Jonathan Javitt and Dr. David Feifel, the visionary leaders of NRx Pharmaceuticals, will deliver the keynote address. The forum takes place before the Oppenheimer event.

The companies are actively shaping the future of mental healthcare, with a focus on innovative approaches like NMDA-targeted therapies and interventional psychiatry clinics (through HOPE Therapeutics' planned acquisitions). Their keynote will be titled "Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD."

NRx Pharmaceuticals' lead candidate, NRX-101, has received FDA Breakthrough Therapy designation for potential use in treating suicidal treatment-resistant bipolar depression and chronic pain. This approach signals a paradigm shift in how complex conditions like suicidal depression and PTSD are approached.

In addition to the Neuroscience Innovation Forum, NRx Pharmaceuticals and HOPE Therapeutics will also attend the BIO CEO & Investor Conference in New York from February 10th to 12th, seeking collaborations and partnerships. The companies are aiming to revolutionize the treatment of conditions like suicidal bipolar depression, chronic pain, and PTSD.

Dr. Javitt will deliver a company update focusing on central nervous system disorders. His presentation will be webcast live on the NRX Events section of their Investor Relations website at 9:20 AM EST, with a replay available for 30 days.

Following the Neuroscience Innovation Forum, Dr. Javitt and Dr. Feifel will attend the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) from February 22 to 25, 2026, in Denver, Colorado, USA. However, there is no specific mention of a conference they will attend on February 8 in San Francisco in the search results.

NRx Pharmaceuticals plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia, further demonstrating their commitment to transforming mental healthcare.

Mental Health Innovations Discussed by NRx Pharmaceuticals and HOPE Therapeutics at Oppenheimer Conference